LABETAKERN 5mg/ml Price

Overview

Welcome to Dwaey, specifically on LABETAKERN 5mg/ml Solution for injection page.
This medicine contains an important and useful components, as it consists of Labetalol hydrochloride.
LABETAKERN 5mg/ml is available in the market in concentration 5mg/ml and in the form of Solution for injection.

KERN PHARMA, S.L is the producer of LABETAKERN 5mg/ml and it is imported from SPAIN, The most popular alternatives of LABETAKERN 5mg/ml are listed downward .

Mode Of Action

Labetalol competitively inhibits the adrenergic stimulation of beta-receptors w/in the myocardium, bronchial and vascular smooth muscle, and alpha1-receptors w/in vascular smooth muscle. It also has some intrinsic beta2-agonist and membrane-stabilising activity.

Indication

• Hypertension
• Hypotensive anaesthesia

Precaution

Phaeochromocytoma, compensated heart failure, nonallergic bronchospasm. Avoid abrupt withdrawal. DM. Hepatic impairment. Perform LFTs. Elderly. Pregnancy and lactation. Lactation: Small amounts excreted; use with caution

Side Effects

• >10% Dizziness (1-20%)
• Lightheadedness (1-20%)
• Nausea (<19%)
• Tingling sensation of scalp (4-12%)
• Fatigue (1-11%) 1-10% Elevated serum blood urea nitrogen (BUN) (<8%)
• Elevated serum creatinine (8%)
• Congestion of nasal sinus (1-6%)
• Orthostatic hypotension (1-5%)
• Absence of ejaculation (<5%)
• Paresthesia (<5%)
• Elevated liver enzymes (4%)
• Diaphoresis (<4%)
• Edema (<2%)
• Bronchospasm (1-2%)
• Dyspnea (1-2%)
• Pruritus (1%)
• Rash (1%)
• Altered taste sense (1%)
• Ventricular arrhythmia (1%; IV) Frequency Not Defined Angioedema
• Bradycardia
• Alopecia
• Cholestatic jaundice
• Depression
• Diabetes insipidus
• Hepatitis
• Raynaud syndrome
• Toxic myopathy
• Urinary retention
• Urticaria
• Raynaud phenomenon Potentially Fatal: Hepatic injury.

Contra indication

2nd and 3rd degree heart block, cardiogenic shock, obstructive airway disease e.g. bronchial asthma, uncompensated heart failure, severe bradycardia, sick sinus syndrome, Prinzmetal's angina, severe peripheral arterial disease.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks